MediciNova Statistics
Total Valuation
MediciNova has a market cap or net worth of $67.93 million. The enterprise value is $37.33 million.
Important Dates
The next estimated earnings date is Tuesday, May 12, 2026, after market close.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MediciNova has 49.22 million shares outstanding. The number of shares has increased by 0.04% in one year.
| Current Share Class | 49.22M |
| Shares Outstanding | 49.22M |
| Shares Change (YoY) | +0.04% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | 2.97% |
| Owned by Institutions (%) | 10.71% |
| Float | 42.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 165.81 |
| Forward PS | n/a |
| PB Ratio | 1.63 |
| P/TBV Ratio | 2.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 91.13 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.16, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.16 |
| Quick Ratio | 8.11 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -25.50% and return on invested capital (ROIC) is -17.53%.
| Return on Equity (ROE) | -25.50% |
| Return on Assets (ROA) | -16.36% |
| Return on Invested Capital (ROIC) | -17.53% |
| Return on Capital Employed (ROCE) | -31.77% |
| Weighted Average Cost of Capital (WACC) | 7.54% |
| Revenue Per Employee | $68,276 |
| Profits Per Employee | -$2.00M |
| Employee Count | 6 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, MediciNova has paid $5,994 in taxes.
| Income Tax | 5,994 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.46% in the last 52 weeks. The beta is 0.60, so MediciNova's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | -6.46% |
| 50-Day Moving Average | 1.54 |
| 200-Day Moving Average | 1.39 |
| Relative Strength Index (RSI) | 44.57 |
| Average Volume (20 Days) | 77,027 |
Short Selling Information
The latest short interest is 203,626, so 0.41% of the outstanding shares have been sold short.
| Short Interest | 203,626 |
| Short Previous Month | 193,563 |
| Short % of Shares Out | 0.41% |
| Short % of Float | 0.48% |
| Short Ratio (days to cover) | 3.35 |
Income Statement
In the last 12 months, MediciNova had revenue of $409,657 and -$12.00 million in losses. Loss per share was -$0.24.
| Revenue | 409,657 |
| Gross Profit | 31,051 |
| Operating Income | -13.28M |
| Pretax Income | -11.99M |
| Net Income | -12.00M |
| EBITDA | -13.26M |
| EBIT | -13.28M |
| Loss Per Share | -$0.24 |
Full Income StatementBalance Sheet
The company has $30.81 million in cash and $211,460 in debt, with a net cash position of $30.60 million or $0.62 per share.
| Cash & Cash Equivalents | 30.81M |
| Total Debt | 211,460 |
| Net Cash | 30.60M |
| Net Cash Per Share | $0.62 |
| Equity (Book Value) | 41.59M |
| Book Value Per Share | 0.84 |
| Working Capital | 27.19M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$9.81 million and capital expenditures -$2,899, giving a free cash flow of -$9.81 million.
| Operating Cash Flow | -9.81M |
| Capital Expenditures | -2,899 |
| Depreciation & Amortization | 20,099 |
| Net Borrowing | n/a |
| Free Cash Flow | -9.81M |
| FCF Per Share | -$0.20 |
Full Cash Flow StatementMargins
| Gross Margin | 7.58% |
| Operating Margin | -3,242.47% |
| Pretax Margin | -2,927.32% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MediciNova does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.03% |
| Shareholder Yield | -0.03% |
| Earnings Yield | -17.66% |
| FCF Yield | -14.45% |
Analyst Forecast
The average price target for MediciNova is $7.50, which is 445.46% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.50 |
| Price Target Difference | 445.46% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 231.77% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MediciNova has an Altman Z-Score of -3.04 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.04 |
| Piotroski F-Score | 1 |
